Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy study of nebulized RPL554 in healthy subjects, allergic asthma, and allergic rhinitis
NL-OMON32512Phase 1Active, not recruiting
- Sponsor
- Verona Pharma
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of ensifentrine in asthma and allergic rhinitis (AR) (2 arms), sponsored by Verona Pharma. Primary endpoint: Safety of nebulized RPL554. Started Mar 2009; status: active, not recruiting.
02
Drugs
ensifentrine
03
Conditions
asthmaallergic rhinitis (AR)
Beyond the preview
Go deeper on NL-OMON32512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32512.